{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:22:12Z","timestamp":1769127732368,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.canrad.2013.04.004","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T05:01:41Z","timestamp":1372309301000},"page":"304-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Radiosensibilisation induite par le v\u00e9muraf\u00e9nib"],"prefix":"10.1016","volume":"17","author":[{"given":"A.","family":"Ducassou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Delannes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2013.04.004_bib0005","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1634\/theoncologist.2009-0090","article-title":"Radiation recall with anticancer agents","volume":"15","author":"Burris","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2013.04.004_bib0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ctrv.2005.07.008","article-title":"Radiation recall: a well recognized but neglected phenomenon","volume":"31","author":"Azria","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.canrad.2013.04.004_bib0015","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0020","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2013.04.004_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2013.04.004_bib0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2013.04.004_bib0035","first-page":"031","article-title":"Effets ind\u00e9sirables cutan\u00e9s des inhibiteurs de BRAF\u00a0: revue syst\u00e9matique","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0045","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2013.04.004_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jrr\/rrs074","article-title":"Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer","volume":"54","author":"Kim","year":"2012","journal-title":"J Radiat Res"},{"key":"10.1016\/j.canrad.2013.04.004_bib0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canrad.2010.11.012","article-title":"Soraf\u00e9nib et radioth\u00e9rapie dans le carcinome h\u00e9patocellulaire","volume":"15","author":"Girard","year":"2011","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2013.04.004_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CAD.0b013e328333d679","article-title":"Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib","volume":"21","author":"Chung","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canrad.2013.04.004_bib0065","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","article-title":"Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032","volume":"98","author":"Sambade","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0070","unstructured":"Alter M, Satzger I, Kapp A, Gutzmer R. Serious skin toxicity for the combination of B-RAF inhibitors and radiotherapy [abstract CO5]. Barcelone\u00a0: 8e Congr\u00e8s de l\u2019European Association of demarto-oncology. 2012\u00a0; Disponible \u00e0 l\u2019adresse\u00a0: http:\/\/www.melanoma2012.com\/program (acc\u00e8s le 3\/6\/2013)."},{"key":"10.1016\/j.canrad.2013.04.004_bib0075","first-page":"4200","article-title":"Vemurafenib and radiosensitization","author":"Boussemart","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0080","first-page":"B96","article-title":"Radioth\u00e9rapie+vemurafenib\u00a0: attention danger","volume":"139","author":"Peuvrel","year":"2013","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0085","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/j.ijrobp.2012.07.788","article-title":"Safety and efficacy of vemurafenib combined with stereotactic radiosurgery for brain metastases in BRAF+ melanoma","volume":"84","author":"Kavanagh","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0090","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/j.ijrobp.2012.07.790","article-title":"Use of vemurafenib, a BRAF inhibitor along with radiation therapy in melanoma brain metastasis","volume":"84","author":"Narayana","year":"2012","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2009.06.015","article-title":"Genetic variants and normal tissue toxicity after radiotherapy: a systematic review","volume":"92","author":"Andreassen","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0100","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0105","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67","author":"Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.canrad.2013.04.004_bib0110","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1\u00a0dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321813001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321813001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:20:24Z","timestamp":1761135624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321813001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1278321813001042"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2013.04.004","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiosensibilisation induite par le v\u00e9muraf\u00e9nib","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2013.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}